The latest update is out from Adicet Bio (ACET).
Adicet Bio, Inc. has unveiled promising preclinical data for its innovative cancer therapy candidate, ADI-270, at the ASGCT Annual Meeting. This new therapy, which targets CD70+ cancers using gamma delta CAR T cell technology, has shown potent effectiveness against various tumor cell lines, including those with low CD70 expression. The treatment demonstrates not only strong anti-tumor responses in vivo but also resilience in suppressive tumor environments, highlighting its potential as a versatile and robust cancer treatment option. With these positive findings, Adicet Bio underscores its commitment to advancing the clinical development of ADI-270 and exploring its broad therapeutic potential.
See more data about ACET stock on TipRanks’ Stock Analysis page.
